Dr. Harry P. Erba
Claim this profileDuke University Medical Center
Expert in Acute Myelogenous Leukemia
Expert in Acute Myeloid Leukemia
18 reported clinical trials
35 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
Global LeaderFLT3 positive
PML-RARA negative
CD123 positive
2Acute Myeloid Leukemia
Global LeaderFLT3 positive
PML-RARA negative
NPM1 positive
Affiliated Hospitals
Clinical Trials Harry P. Erba is currently running
DSP-5336
for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Recruiting1 award Phase 1 & 215 criteria
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
More about Harry P. Erba
Clinical Trial Related7 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Harry P. Erba has experience with
- Venetoclax
- Azacitidine
- Cytarabine
- Daunorubicin Hydrochloride
- MBG453
- Blinatumomab
Breakdown of trials Harry P. Erba has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Relapse
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Harry P. Erba specialize in?
Harry P. Erba focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved FLT3 positive patients, or patients who are PML-RARA negative.
Is Harry P. Erba currently recruiting for clinical trials?
Yes, Harry P. Erba is currently recruiting for 9 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Harry P. Erba has studied deeply?
Yes, Harry P. Erba has studied treatments such as Venetoclax, Azacitidine, Cytarabine.
What is the best way to schedule an appointment with Harry P. Erba?
Apply for one of the trials that Harry P. Erba is conducting.
What is the office address of Harry P. Erba?
The office of Harry P. Erba is located at: Duke University Medical Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.